HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial
Year: 2024
Type: article
Study design: Clinical Trial
Source: The Lancet HIV
Authors: David A Wohl, Christoph D Spinner, Jason Flamm, C Bradley Hare, Susanne Doblecki-Lewis, Peter J Ruane, Jean-Michel Molina, Anthony Mills, Cynthia Brinson, Moti Ramgopal, Amanda Clarke, Gordon Crofoot, Claudia Martorell, Christoph Carter, Stephanie Cox, J Carlo Hojilla, Yongwu Shao, Moupali Das, Alexander Kintu, Jared M Baeten, Robert M Grant, Karam Mounzer, Kenneth Mayer
Institutions: University of North Carolina at Chapel Hill, Technical University of Munich, Kaiser Permanente, Kaiser Permanente Sacramento Medical Center, Kaiser Permanente San Francisco Medical Center, University of Miami, Ruane Medical, Inserm, Université Paris Cité, Génomes, biologie cellulaire et thérapeutiques, Hôpital Lariboisière, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Gilead Sciences (United States), University of California, San Francisco, San Francisco AIDS Foundation, Philadelphia Fight, Beth Israel Deaconess Medical Center, Fenway Health
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4400625136